International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8253059
Original Article
A Study on Effectiveness of Middle Meatalantrostomy in Treatment of Chronic Maxillary Sinusitis
 ,
 ,
Published
Aug. 14, 2023
Abstract

Background: Chronic maxillary sinusitis is an inflammation of the maxillary sinus lasting for more than 12 weeks. It is diagnosed by typical symptoms and/or a computed tomography scan and/or nasoendoscopic changes.

After failure of maximum conservative therapy, functional endoscopic sinus surgery (FESS) aims to restore normal sinus function and ventilation though natural ostia. Traditionally in maxillary sinus surgery, FESS was initiated with the removal of the uncinate combined with middle meatalantrostomy.

Aim: To study the effectiveness of middle meatalantrostomy in the treatment of chronic maxillary sinusitis, with respect to the treatment of nasal discharge, nasal obstruction, facial pain, headache, and olfactory alteration.

Material and Methods: 54 Patients with chronic maxillary rhinosinusitis refractory to medical line of treatment were the study subject. Patients symptom profile, CT PNS, DNE findings preoperatively were documented. All the 54 patients underwent middle meatalantrostomy. Post operatively patients were followed up on day 7, day 30 and day 90. They were assessed for relief in symptoms and DNE on each follow up day.

Results: 54 Patients with chronic maxillary sinusitis were assessed, 90 days after surgery 100% (n=54) of the patients had improvement in symptoms of nasal discharge, headache and olfactory alteration. 98% (n=53) of the patients appreciated improvement in nasal obstruction and facial pain.

Conclusion: Results suggest that middle meatalantrostomy is effective in relieving the symptoms of chronic maxillary sinusitis such as nasal obstruction, nasal discharge, facial pain, headache, and olfactory alteration.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
2150 Views
499 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved